Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NGNE, ALPN, URGN, ABVX, EOLS, and represent 31.96% of Great Point Partners's stock portfolio.
- Added to shares of these 10 stocks: VRDN (+$23M), ESPR (+$21M), MNMD (+$19M), DNTH (+$19M), Outlook Therapeutics (+$18M), ACLX (+$18M), DVAX (+$16M), INSM (+$15M), ABVX (+$13M), JSPR (+$12M).
- Started 10 new stock positions in MNMD, DNTH, JSPR, ESPR, DVAX, VRDN, AUTL, Outlook Therapeutics, Kyverna Therapeutics, Helix Acquisition Corp Ii Cl A.
- Reduced shares in these 10 stocks: ALPN (-$102M), RARE (-$31M), RAPT (-$27M), , PCVX (-$23M), CYTK (-$21M), TRML (-$18M), IMCR (-$12M), Karuna Therapeutics Ord (-$9.6M), SRPT (-$7.7M).
- Sold out of its positions in AXSM, Karuna Therapeutics Ord, RAPT, SRPT, TRML, RARE, PCVX, ALKS, MURA.
- Great Point Partners was a net seller of stock by $-72M.
- Great Point Partners has $642M in assets under management (AUM), dropping by 9.36%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Great Point Partners
Great Point Partners holds 35 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Neurogene (NGNE) | 8.0 | $51M | 1.0M | 50.90 |
|
|
| Alpine Immune Sciences (ALPN) | 7.0 | $45M | -69% | 1.1M | 39.64 |
|
| Urogen Pharma (URGN) | 6.1 | $39M | 2.6M | 15.00 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 5.5 | $36M | +60% | 2.5M | 14.30 |
|
| Evolus (EOLS) | 5.3 | $34M | +22% | 2.5M | 14.00 |
|
| Pliant Therapeutics (PLRX) | 4.3 | $28M | 1.9M | 14.90 |
|
|
| Apogee Therapeutics (APGE) | 4.1 | $27M | 400k | 66.45 |
|
|
| Aerovate Therapeutics (AVTE) | 4.1 | $26M | -14% | 888k | 29.57 |
|
| Miragen Therapeutics (VRDN) | 3.6 | $23M | NEW | 1.3M | 17.51 |
|
| Anaptysbio Inc Common (ANAB) | 3.4 | $22M | 977k | 22.52 |
|
|
| Esperion Therapeutics (ESPR) | 3.3 | $21M | NEW | 8.0M | 2.68 |
|
| Insmed Com Par $.01 (INSM) | 3.3 | $21M | +243% | 776k | 27.13 |
|
| Arcellx Common Stock (ACLX) | 3.3 | $21M | +521% | 300k | 69.55 |
|
| Xenon Pharmaceuticals (XENE) | 3.1 | $20M | -23% | 456k | 43.05 |
|
| Mind Medicine Mindmed Com New (MNMD) | 2.9 | $19M | NEW | 2.0M | 9.40 |
|
| Dianthus Therapeutics (DNTH) | 2.9 | $19M | NEW | 625k | 30.00 |
|
| Outlook Therapeutics | 2.8 | $18M | NEW | 1.5M | 11.94 |
|
| Amicus Therapeutics (FOLD) | 2.7 | $18M | +16% | 1.5M | 11.78 |
|
| Ocular Therapeutix (OCUL) | 2.5 | $16M | +146% | 1.7M | 9.10 |
|
| Dynavax Technologies Corp Com New (DVAX) | 2.4 | $16M | NEW | 1.3M | 12.41 |
|
| Cytokinetics Com New (CYTK) | 2.2 | $14M | -59% | 202k | 70.11 |
|
| Optinose (OPTN) | 2.0 | $13M | 8.8M | 1.46 |
|
|
| Jasper Therapeutics Com New (JSPR) | 1.9 | $12M | NEW | 408k | 29.36 |
|
| Intra Cellular Therapies (ITCI) | 1.6 | $10M | +35% | 150k | 69.20 |
|
| Merus N V (MRUS) | 1.6 | $10M | +1016% | 223k | 45.03 |
|
| Vistagen Therapeutics Ord (VTGN) | 1.5 | $9.8M | 1.9M | 5.28 |
|
|
| Terns Pharmaceuticals (TERN) | 1.3 | $8.6M | 1.3M | 6.56 |
|
|
| Immunocore Hldgs Ads (IMCR) | 1.2 | $7.5M | -60% | 115k | 65.00 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.2 | $7.4M | NEW | 1.2M | 6.38 |
|
| Puma Biotechnology (PBYI) | 1.1 | $7.1M | +22% | 1.3M | 5.30 |
|
| Zura Bio Class A Ord Shs (ZURA) | 1.1 | $7.1M | -16% | 2.8M | 2.57 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs | 0.8 | $5.2M | NEW | 500k | 10.40 |
|
| Spyre Therapeutics Com New (SYRE) | 0.7 | $4.7M | 125k | 37.93 |
|
|
| Kyverna Therapeutics | 0.6 | $3.7M | NEW | 150k | 24.84 |
|
| Arvinas Ord (ARVN) | 0.5 | $2.9M | -69% | 71k | 41.28 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2024 Q1 filed May 15, 2024
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022
- Great Point Partners 2022 Q2 filed Aug. 15, 2022
- Great Point Partners 2022 Q1 filed May 16, 2022
- Great Point Partners 2021 Q4 filed Feb. 14, 2022
- Great Point Partners 2021 Q3 filed Nov. 15, 2021
- Great Point Partners 2021 Q2 filed Aug. 16, 2021
- Great Point Partners 2021 Q1 filed May 17, 2021
- Great Point Partners 2020 Q4 filed Feb. 16, 2021
- Great Point Partners 2020 Q3 filed Nov. 16, 2020
- Great Point Partners 2020 Q2 filed Aug. 14, 2020